Cherry EM et al. demonstrated that older age, secondary AML, and RUNX1 mutations favor a response to Ven/Aza over IC, whereas the intermediate-risk monocytic AML group showed a preference for IC over Ven/Aza [24]. Here, RUNX1 is linked to acute myeloid leukemia.